Oculis Holding AG (ICE:OCS)
Iceland · Delayed Price · Currency is ISK | Market Cap | 97.86B -23.5% |
| Revenue (ttm) | 174.30M +49.9% |
| Net Income | -14.68B |
| EPS | -267.42 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 580 |
| Open | 1,660.00 |
| Previous Close | 1,705.00 |
| Day's Range | 1,640.00 - 1,665.00 |
| 52-Week Range | 1,290.00 - 4,180.00 |
| Beta | 0.20 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Oculis Holding AG
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological da... [Read more]
Financial Performance
In 2025, Oculis Holding AG's revenue was 1.20 million, an increase of 74.78% compared to the previous year's 686,000. Losses were -98.96 million, 15.4% more than in 2024.
Financial numbers in CHF Financial StatementsNews
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
ZUG, Switzerland, July 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
ZUG, Switzerland, July 2, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophth...
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to ad...
Oculis Holding AG Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Following a setback in the DIAMOND trials, resources are now focused on advancing Privosegtor in neuro-ophthalmology and Licaminlimab in dry eye, both with innovative clinical strategies. Privosegtor targets large unmet needs and market potential, while a strong cash position supports ongoing development.
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
ZUG, Switzerland, June 9, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical ne...
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant u...
Oculis Holding AG Slides: Study update presentation
Oculis Holding AG has posted slides in relation to its latest quarterly earnings report, which was published on June 4, 2026.
Oculis Holding AG Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Oculis Holding AG (NASDAQ: OCS) or certain of its executive officers violated federal securities laws. The in...
Oculis Holding AG Transcript: Study result
Phase III trials of OCS-01 in DME failed to meet primary and key secondary endpoints, despite showing significant retinal thickness reduction and a favorable safety profile. No FDA filing will be pursued, and resources will shift to late-stage assets Privosegtor and licaminlimab.
Oculis Holding AG Press release: Study result
Oculis Holding AG issued a press release on May 29, 2026, disclosing material business information to investors.
Oculis Holding AG Slides: Study result
Oculis Holding AG has posted slides in relation to its latest quarterly earnings report, which was published on May 29, 2026.
Oculis Holding AG trading resumes
16:21 EDT Oculis (OCS) Holding AG trading resumes
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met The secondary endpoint of retinal thickness showed a substantial...
Oculis Holding AG trading halted, news pending
14:43 EDT Oculis (OCS) Holding AG trading halted, news pending
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
ZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2026 Annual General Meeting held on May...
Oculis Holding AG Transcript: AGM 2026
The meeting approved all agenda items, including financial statements, board elections, compensation, and capital increases. Clinical programs advanced significantly, with major trial readouts expected in 2026 and 2027. Net loss increased due to R&D investment.
Oculis Holding AG Slides: FY 2026
Oculis Holding AG has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 13, 2026.
Oculis Reports Q1 2026 Financial Results and Provides Company Update
ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pipeline Advancing as Planned, Leading with OCS-01 Key Milestone Completion of LPLV in Both DIAMOND Phase 3 Trials; Data Readout on Track for June 20...
Oculis Holding AG Earnings release: Q1 2026
Oculis Holding AG released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
ZUG, Switzerland, May 7 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical need...
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular edema (DME) management Oculis is on track to report top...
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
ZUG, Switzerland, May 01, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant u...
Oculis Publishes Invitation to the Annual General Meeting
ZUG, Switzerland, April 21, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), today published the invitation to the 2026 Annual General Meeting, which will be held on May...
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant...
Oculis Holding AG Transcript: 25th Annual Needham Virtual Healthcare Conference
Three late-stage assets are advancing in large ophthalmic and neuro-ophthalmic markets, with OCS-01 phase III results expected in June, licaminlimab targeting a genotype-defined dry eye population, and privosegtor in registrational trials for rare optic neuropathies. Strong financials and regulatory support position the pipeline for multiple milestones through 2027.